Earnings (loss) per share (Tables)

9 Months Ended

Sep. 30, 2025

Basic and diluted earnings (loss) per share attributable to Teva’s ordinary shareholders for the three and nine months ended September 30, 2025, are calculated as follows:


	Three Months Ended					Nine Months Ended
	September 30,					September 30,
(U.S. $ in millions except per share amounts)	2025		2024			2025		2024
Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
Net income (loss) attributable to Teva’s ordinary shareholders	$	433	$	(437	)	$	930	$	(1,422	)

Shares (denominator):
Weighted average shares outstanding		1,147		1,133			1,144		1,130

Basic earnings (loss) attributable to Teva’s ordinary shareholders	$	0.38	$	(0.39	)	$	0.81	$	(1.26	)

Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
Net income (loss) attributable to Teva’s ordinary shareholders	$	433	$	(437	)	$	930	$	(1,422	)

Shares (denominator):
Weighted average shares outstanding		1,147		1,133			1,144		1,130
Diluted effect of stock options, RSUs and PSUs		17		—			16		—

Total dilutive shares outstanding		1,164		1,133			1,160		1,130

Diluted earnings (loss) attributable to Teva’s ordinary shareholders	$	0.37	$	(0.39	)	$	0.80	$	(1.26	)